Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 481

1.

Free-Wilson Analysis of Comprehensive Data on Phosphoinositide-3-kinase (PI3K) Inhibitors Reveals Importance of N-Methylation for PI3Kδ Activity.

Barnes L, Blaber H, Brooks DTK, Byers L, Buckley D, Byron ZC, Chilvers RG, Cochrane L, Cooney E, Damian HA, Francis L, Fu He D, Grace JMJ, Green HJ, Hogarth EJP, Jusu L, Killalea CE, King O, Lambert J, Lee ZJ, Lima NS, Long CL, Mackinnon ML, Mahdy S, Matthews-Wright J, Millward MJ, Meehan MF, Merrett C, Morrison L, Parke HRI, Payne C, Payne L, Pike C, Seal A, Senior AJ, Smith KM, Stanelyte K, Stillibrand J, Szpara R, Taday FFH, Threadgould AM, Trainor RJ, Waters J, Williams O, Wong CKW, Wood K, Barton N, Gruszka A, Henley Z, Rowedder JE, Cookson R, Jones KL, Nadin A, Smith IE, Macdonald SJF, Nortcliffe A.

J Med Chem. 2019 Nov 6. doi: 10.1021/acs.jmedchem.9b01499. [Epub ahead of print]

PMID:
31647659
2.

Early enrichment of ESR1 mutations and the impact on gene expression in pre-surgical primary breast cancer treated with aromatase inhibitors.

Leal MF, Haynes BP, Schuster EF, Yeo B, Afentakis M, Zabaglo L, Martins V, Buus R, Dodson A, Cheang MCU, Smith IE, Martin LA, Dowsett M.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.1129.2019. doi: 10.1158/1078-0432.CCR-19-1129. [Epub ahead of print]

PMID:
31548345
3.

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.

Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC.

JAMA Oncol. 2019 Aug 1. doi: 10.1001/jamaoncol.2019.1838. [Epub ahead of print]

PMID:
31369045
4.

The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors.

Deaton DN, Do Y, Holt J, Jeune MR, Kramer HF, Larkin AL, Orband-Miller LA, Peckham GE, Poole C, Price DJ, Schaller LT, Shen Y, Shewchuk LM, Stewart EL, Stuart JD, Thomson SA, Ward P, Wilson JW, Xu T, Guss JH, Musetti C, Rendina AR, Affleck K, Anders D, Hancock AP, Hobbs H, Hodgson ST, Hutchinson J, Leveridge MV, Nicholls H, Smith IED, Somers DO, Sneddon HF, Uddin S, Cleasby A, Mortenson PN, Richardson C, Saxty G.

Bioorg Med Chem. 2019 Apr 15;27(8):1456-1478. doi: 10.1016/j.bmc.2019.02.017. Epub 2019 Feb 11.

PMID:
30858025
5.

PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase Is Inhibited by Covalent Binding.

Tinworth CP, Lithgow H, Dittus L, Bassi ZI, Hughes SE, Muelbaier M, Dai H, Smith IED, Kerr WJ, Burley GA, Bantscheff M, Harling JD.

ACS Chem Biol. 2019 Mar 15;14(3):342-347. doi: 10.1021/acschembio.8b01094. Epub 2019 Feb 27.

PMID:
30807093
6.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

7.

Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.

Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Quang LH, Han PT, Khoa PH, Dinh NV, To TV, Clemons M, Smith IE, Dowsett M.

NPJ Breast Cancer. 2017 Nov 27;3:47. doi: 10.1038/s41523-017-0049-z. eCollection 2017.

8.

De-escalating and escalating systemic therapy of early breast cancer.

Smith IE, Okines AFC.

Breast. 2017 Aug;34 Suppl 1:S5-S9. doi: 10.1016/j.breast.2017.06.019. Epub 2017 Jul 8. No abstract available.

PMID:
28694014
9.

Reply to R. Goncalves et al.

Smith IE.

J Clin Oncol. 2017 Aug 10;35(23):2719. doi: 10.1200/JCO.2017.73.2214. Epub 2017 Jun 5. No abstract available.

PMID:
28581885
10.

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.

Sheri A, Smith IE, Hills M, Jones RL, Johnston SR, Dowsett M.

Breast Cancer Res Treat. 2017 Jul;164(2):395-400. doi: 10.1007/s10549-017-4266-9. Epub 2017 Apr 26.

11.

Hospital outcomes and long-term survival after referral to a specialized weaning unit.

Davies MG, Quinnell TG, Oscroft NS, Clutterbuck SP, Shneerson JM, Smith IE.

Br J Anaesth. 2017 Apr 1;118(4):563-569. doi: 10.1093/bja/aex031.

12.

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.

Detre SI, Ashley S, Mohammed K, Smith IE, Powles TJ, Dowsett M.

Cancer Prev Res (Phila). 2017 Mar;10(3):171-176. doi: 10.1158/1940-6207.CAPR-16-0247-T. Epub 2017 Jan 18.

13.

Research needs in breast cancer.

Cardoso F, Harbeck N, Barrios CH, Bergh J, Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH, Sledge GW, Smith IE, Gelmon KA.

Ann Oncol. 2017 Feb 1;28(2):208-217. doi: 10.1093/annonc/mdw571.

PMID:
27831505
14.

Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.

Klintman M, Buus R, Cheang MC, Sheri A, Smith IE, Dowsett M.

Clin Cancer Res. 2016 May 15;22(10):2405-16. doi: 10.1158/1078-0432.CCR-15-1488.

15.

Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.

Kordbacheh T, Law WY, Smith IE.

Breast. 2016 Apr;26:54-8. doi: 10.1016/j.breast.2015.11.005. Epub 2016 Jan 22. Review.

PMID:
27017242
16.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
17.

Characterization and quantification of suspended sediment sources to the Manawatu River, New Zealand.

Vale SS, Fuller IC, Procter JN, Basher LR, Smith IE.

Sci Total Environ. 2016 Feb 1;543(Pt A):171-186. doi: 10.1016/j.scitotenv.2015.11.003. Epub 2015 Nov 12.

PMID:
26580740
18.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

19.

Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab.

Yeo B, Kotsori K, Mohammed K, Walsh G, Smith IE.

Breast. 2015 Dec;24(6):751-7. doi: 10.1016/j.breast.2015.09.008. Epub 2015 Oct 9.

PMID:
26456898
20.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728

Supplemental Content

Loading ...
Support Center